Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia.

Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A.

Exp Neurol. 2010 Sep;225(1):210-8. doi: 10.1016/j.expneurol.2010.06.017. Epub 2010 Jun 28.

2.

Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents.

Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, Nehama D, Rajadas J, Longo FM.

J Clin Invest. 2010 May;120(5):1774-85. doi: 10.1172/JCI41356. Epub 2010 Apr 19.

3.

Age-related differences in MK-801 induced behaviors in dopamine D3 receptor knock out mice.

Iarkov AV, Der TC, Joyce JN.

Eur J Pharmacol. 2010 Feb 10;627(1-3):177-84. doi: 10.1016/j.ejphar.2009.11.012. Epub 2009 Nov 10.

PMID:
19909735
4.

Locomotor activity induced by MK-801 is enhanced in dopamine D3 receptor knockout mice but suppression by dopamine D3/D2 antagonists does not occur through the dopamine D3 receptor.

Yarkov AV, Der TC, Joyce JN.

Eur J Pharmacol. 2010 Feb 10;627(1-3):167-72. doi: 10.1016/j.ejphar.2009.10.068. Epub 2009 Nov 10.

PMID:
19900441
5.

c-Fos expression associated with reinstatement of cocaine-seeking behavior by response-contingent conditioned cues.

Kufahl PR, Zavala AR, Singh A, Thiel KJ, Dickey ED, Joyce JN, Neisewander JL.

Synapse. 2009 Oct;63(10):823-35. doi: 10.1002/syn.20666.

6.

Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.

Duka T, Duka V, Joyce JN, Sidhu A.

FASEB J. 2009 Sep;23(9):2820-30. doi: 10.1096/fj.08-120410. Epub 2009 Apr 15.

7.

Upregulation of Arc mRNA expression in the prefrontal cortex following cue-induced reinstatement of extinguished cocaine-seeking behavior.

Zavala AR, Osredkar T, Joyce JN, Neisewander JL.

Synapse. 2008 Jun;62(6):421-31. doi: 10.1002/syn.20502.

8.

Microglial responses to dopamine in a cell culture model of Parkinson's disease.

Mastroeni D, Grover A, Leonard B, Joyce JN, Coleman PD, Kozik B, Bellinger DL, Rogers J.

Neurobiol Aging. 2009 Nov;30(11):1805-17. doi: 10.1016/j.neurobiolaging.2008.01.001. Epub 2008 Mar 5.

9.

PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis.

Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, Libri V, Leppert D, Beach TG.

Brain. 2007 Oct;130(Pt 10):2607-15. Epub 2007 Aug 13.

PMID:
17698496
10.

Dopamine D3 receptor agonists for protection and repair in Parkinson's disease.

Joyce JN, Millan MJ.

Curr Opin Pharmacol. 2007 Feb;7(1):100-5. Epub 2006 Dec 13. Review.

PMID:
17174156
11.

Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia.

Bychkov ER, Gurevich VV, Joyce JN, Benovic JL, Gurevich EV.

Neurobiol Aging. 2008 Mar;29(3):379-96. Epub 2006 Nov 27.

12.

In vivo brain microdialysis studies on the striatal dopamine and serotonin release in zitter mutant rats.

Yoshimoto K, Nishimura A, Hattori H, Joyce JN, Yoshida T, Hioki C, Kogure A, Ueda S.

Mech Ageing Dev. 2006 Jul;127(7):628-32. Epub 2006 Apr 18.

PMID:
16620918
13.

Progressive dopaminergic neurodegeneration of substantia nigra in the zitter mutant rat.

Nakadate K, Noda T, Sakakibara S, Kumamoto K, Matsuura T, Joyce JN, Ueda S.

Acta Neuropathol. 2006 Jul;112(1):64-73. Epub 2006 Apr 12.

PMID:
16609850
14.

Dopamine D3 receptor antagonists as therapeutic agents.

Joyce JN, Millan MJ.

Drug Discov Today. 2005 Jul 1;10(13):917-25. Review.

PMID:
15993811
15.

Degeneration of dopaminergic neurons in the substantia nigra of zitter mutant rat and protection by chronic intake of Vitamin E.

Ueda S, Sakakibara S, Nakadate K, Noda T, Shinoda M, Joyce JN.

Neurosci Lett. 2005 Jun 3;380(3):252-6. Epub 2005 Feb 8.

PMID:
15862896
18.

Age-related changes in nigrostriatal dopaminergic function are accentuated in +/- brain-derived neurotrophic factor mice.

Dluzen DE, McDermott JL, Anderson LI, Kucera J, Joyce JN, Osredkar T, Walro JM.

Neuroscience. 2004;128(1):201-8.

PMID:
15450367
19.
20.
21.

Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers.

Beach TG, Walker DG, Sue LI, Newell A, Adler CC, Joyce JN.

J Neuropathol Exp Neurol. 2004 Apr;63(4):329-37.

PMID:
15099023
22.

Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.

Joyce JN, Der TC, Renish L, Osredkar T, Hagner D, Reploge M, Sakakibara S, Ueda S.

Exp Neurol. 2004 May;187(1):178-89.

PMID:
15081599
23.

S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.

Millan MJ, Di Cara B, Hill M, Jackson M, Joyce JN, Brotchie J, McGuire S, Crossman A, Smith L, Jenner P, Gobert A, Peglion JL, Brocco M.

J Pharmacol Exp Ther. 2004 Jun;309(3):921-35. Epub 2004 Feb 20.

PMID:
14978195
24.

Methamphetamine-induced loss of striatal dopamine innervation in BDNF heterozygote mice does not further reduce D3 receptor concentrations.

Joyce JN, Renish L, Osredkar T, Walro JM, Kucera J, Dluzen DE.

Synapse. 2004 Apr;52(1):11-9.

PMID:
14755628
25.

Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice.

Yarkov AV, Hanger D, Reploge M, Joyce JN.

Pharmacol Biochem Behav. 2003 Dec;76(3-4):551-62.

PMID:
14643855
26.
27.
28.

Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors.

Joyce JN, Ryoo HL, Beach TB, Caviness JN, Stacy M, Gurevich EV, Reiser M, Adler CH.

Brain Res. 2002 Nov 15;955(1-2):138-52.

PMID:
12419530
29.

Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs.

Joyce JN.

Pharmacol Ther. 2001 May-Jun;90(2-3):231-59. Review.

PMID:
11578658
30.
31.

Ventral striatal D(3) receptors and Parkinson's Disease.

Joyce JN, Ryoo H, Gurevich EV, Adler C, Beach T.

Parkinsonism Relat Disord. 2001 Jul;7(3):225-230.

PMID:
11331190
33.

Ontogeny of the dopamine D2 receptor mRNA expressing cells in the human hippocampal formation and temporal neocortex.

Gurevich EV, Kordower JH, Joyce JN.

J Chem Neuroanat. 2000 Dec;20(3-4):307-25.

PMID:
11207428
34.

The zitter mutant rat exhibits loss of D3 receptors with degeneration of the dopamine system.

Joyce JN, Yoshimoto K, Ueda S.

Neuroreport. 2000 Jul 14;11(10):2173-5.

PMID:
10923665
35.
36.

D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics.

Joyce JN, Gurevich EV.

Ann N Y Acad Sci. 1999 Jun 29;877:595-613. Review.

PMID:
10415673
37.

Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra.

Ma SY, Ciliax BJ, Stebbins G, Jaffar S, Joyce JN, Cochran EJ, Kordower JH, Mash DC, Levey AI, Mufson EJ.

J Comp Neurol. 1999 Jun 21;409(1):25-37.

PMID:
10363709
38.

Timing: A critical determinant of the functional consequences of neonatal 6-OHDA lesions.

Neal-Beliveau BS, Joyce JN.

Neurotoxicol Teratol. 1999 Mar-Apr;21(2):129-40.

PMID:
10192273
39.

Developmental regulation of expression of the D3 dopamine receptor in rat nucleus accumbens and islands of Calleja.

Gurevich EV, Himes JW, Joyce JN.

J Pharmacol Exp Ther. 1999 Apr;289(1):587-98.

PMID:
10087054
40.
41.

There is a limited critical period for dopamine's effects on D1 receptor expression in the developing rat neostriatum.

Thomas WS, Neal-Beliveau BS, Joyce JN.

Brain Res Dev Brain Res. 1998 Nov 1;111(1):99-106.

PMID:
9804909
42.

Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease.

Joyce JN, Murray AM, Hurtig HI, Gottlieb GL, Trojanowski JQ.

Neuropsychopharmacology. 1998 Dec;19(6):472-80.

43.

Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.

Ryoo HL, Pierrotti D, Joyce JN.

Mov Disord. 1998 Sep;13(5):788-97.

PMID:
9756147
44.
45.

Dopamine D2 receptor bands in normal human temporal cortex are absent in Alzheimer's disease.

Joyce JN, Myers AJ, Gurevich E.

Brain Res. 1998 Feb 16;784(1-2):7-17.

PMID:
9518532
46.

Dopamine D2 receptor mRNA is expressed in maturing neurons of the human hippocampal and subicular fields.

Gurevich EV, Kordower J, Joyce JN.

Neuroreport. 1997 Nov 10;8(16):3605-10.

PMID:
9427335
48.

Alterations in the cortical serotonergic system in schizophrenia: a postmortem study.

Gurevich EV, Joyce JN.

Biol Psychiatry. 1997 Oct 1;42(7):529-45.

PMID:
9376449
49.

Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study.

Goldsmith SK, Shapiro RM, Joyce JN.

Arch Gen Psychiatry. 1997 Jul;54(7):649-58.

PMID:
9236549
50.

Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia.

Joyce JN, Meador-Woodruff JH.

Neuropsychopharmacology. 1997 Jun;16(6):375-84. Review.

Supplemental Content

Loading ...
Support Center